Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind, placebo-controlled study of perampanel as adjunctive therapy in refractory partial-onset seizures with open-label extension
2020-002109-24Phase 3
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2020
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of perampanel in focal-onset epileptic seizures and epilepsy (4 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Percent change in seizure frequency for all partial-onset seizures.
02
Drugs
perampanel
03
Conditions
focal-onset epileptic seizuresepilepsy
Beyond the preview
Go deeper on 2020-002109-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002109-24.